NHS England has made a revised offer to Vertex Pharmaceutical, which makes the cystic fibrosis drug Orkambi, reported Sky News.
Negotiations with the company have been stalled since July last year when the manufacturer declined an NHS offer of 500 million pounds over five years for three treatments, two in production and one in development.
When negotiations broke down, NHS England revealed Vertex had asked for 105 000 pounds per patient, which the manufacturer said was in line with fees paid in other territories.
The latest NHS offer is for a higher, but undisclosed fee and includes only two of three drugs, Orkambi and another cystic fibrosis drug, Symkevi.
It proposes a review after two years, at which point Vertex would pay a rebate if the drugs have not proved as effective as they claim.
Vertex noted that the new NHS offer "reflected the same annual spend" as the July 2018 offer. A spokesman said the UK list price of Orkambi is 104 000 pounds per patient per year, but that "should not be interpreted as the offer made by Vertex to NHS England for all our current and future [cystic fibrosis] medicines."
To read more NewsPoints articles, click here.